Skip to main content

Investment Bank Downgrades Waters on Q1 Profit Decline

NEW YORK, April 28 (GenomeWeb News) - Merrill Lynch yesterday cut Waters' stock to 'Neutral' from 'Buy' after the company said first-quarter income declined year over year.


As GenomeWeb News reported, Waters on Wednesday said first-quarter sales rose 8.2 percent atop increasing R&D spending and a narrowed profit.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.